Clarient Systems Corporation

Clarient is a leading oncology diagnostics company dedicated to delivering advanced, precision-driven cancer testing and pathology services. Through its wholly owned subsidiary, Clarient Diagnostic Services, Clarient combines cutting-edge technologies such as immunohistochemistry (IHC), flow cytometry, molecular sequencing, cytogenetics, and other laboratory modalities to analyze and characterize tumors — enabling accurate diagnosis, prognosis, and guiding personalized treatment decisions. Serving pathologists, oncologists, hospitals, and biopharmaceutical clients, Clarient has provided a broad menu of cancer diagnostic tests covering common solid tumors (e.g., breast, lung, colon, prostate, ovarian) as well as hematologic malignancies like leukemia and lymphoma. Clarient also supports drug development and clinical trials by offering diagnostic and biomarker services to pharmaceutical companies. Its mission centers on improving patient care and reducing cost and delay in therapy by offering high-quality diagnostics through a centralized reference lab, making sophisticated cancer testing accessible even to providers without in-house specialized labs. Over the years, Clarient’s innovations and contributions to precision oncology helped advance the field of biomarker-based diagnostics and personalized medicine. After being acquired by NeoGenomics in 2015, Clarient’s legacy continues — its diagnostic capabilities and expertise now form an integral part of NeoGenomics’ comprehensive cancer-testing services.